What Centre François Baclesse does

Centre François Baclesse is a French non-profit comprehensive cancer center (centre de lutte contre le cancer, CLCC) located in Caen, Normandy, and one of the 18 institutions that make up the Unicancer network. It pursues a triple mission of care, research, and teaching, serving cancer patients from Normandy, nationally, and internationally. In 2023 the center employed 1,162 staff including 165 doctors and scientists, treated 27,969 patients, and enrolled 623 patients in interventional clinical trials.

The center operates one of France's most comprehensive oncology technical platforms. Treatment services include proton therapy (Proteus One with pencil-beam scanning, installed 2018, third such site in France), external beam radiotherapy (CyberKnife, Tomotherapy, Rapid'Arc, Halcyon with Intrabeam intraoperative radiotherapy), and brachytherapy (the only dedicated unit in Normandy). Diagnostic and therapeutic capabilities span nuclear medicine with Gallium-68 DOTATOC PET and LUTATHERA theranostics, interventional radiology (cryoablation, radiofrequency ablation, cementoplasty), full surgical oncology across multiple specialties, and supportive care. Research is anchored by two Inserm units (U1086 ANTICIPE and U1245) and platforms including the Plateforme Cancer et Cognition producing the CogBOOST cognitive rehabilitation solution.

Baclesse is funded as a public healthcare institution applying French National Health Insurance (Assurance Maladie) tariffs with no private or extra billing, supplemented by donations, patronage events, and research funding. The center holds OECI Comprehensive Cancer Center accreditation (renewed June 2026), EUSOMA breast certification (first in France), ISO 9001:2015 certification for its data processing center, and HAS quality recognition. Distribution is direct-to-patient through physician referral or self-booking with a prescription, plus a satellite radiotherapy site at CH Cherbourg and dedicated international patient services for self-pay proton therapy cases.

Name

Centre François Baclesse

Legal name

Centre François Baclesse

Website

https://baclesse.fr

Company type

Private

Founded year

1925

Operating status

Operating

Headcount range

11–50 employees

Short description

Centre François Baclesse is a French non-profit comprehensive cancer center in Caen, part of the 18-center Unicancer network, providing diagnosis, multi-modality treatment, clinical research, and teaching across all cancer types.

Ownership category

akta.pro rank

Product category

Cancer Treatment and Oncology Services

NAICS

Medical and Diagnostic Laboratories (62151), Diagnostic Imaging Centers (621512)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Radiation Oncology (HLAKAFAC), Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

Keywords

• Oncology treatment services
• Proton therapy
• Radiation oncology
• Cancer research
• Clinical trials

Headquarters

HQ city

Caen

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Healthcare Services Revenue: Centre François Baclesse operates as a public healthcare institution providing cancer treatment services. The center applies rates set by the French National Health Insurance (Assurance Maladie) and does not charge private sector or extra fees. Medical transport is covered by Assurance Maladie when prescribed by center doctors and justified by patient's health condition.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Centre François Baclesse is a comprehensive cancer treatment center providing integrated oncology services across diagnosis, treatment, research, and teaching. Its core offerings include proton therapy, external radiotherapy, brachytherapy, nuclear medicine, interventional radiology, oncological surgery, supportive care, and clinical research. The center serves as one of 18 French comprehensive cancer centers under the Unicancer network.

Product overview

Centre François Baclesse is one of 18 French cancer centers (member of Unicancer network) providing comprehensive cancer care through integrated treatment services. The center offers a unified portfolio of oncology services including proton therapy (Protonthérapie), external radiotherapy (Radiothérapie with CyberKnife®, Tomotherapy®, Rapid'Arc®, Halcyon® systems), and brachytherapy (Curiethérapie). Additional core services include nuclear medicine with advanced PET-CT and Gallium-68 imaging, diagnostic and interventional radiology, surgical oncology across multiple specialties (ENT, breast, gynecological, digestive, thyroid, skin cancer), and supportive care services. The center operates dedicated research units including clinical research programs with 623 patients in trials, the Institut Normand du Sein (EUSOMA-certified breast institute), and the Cancer and Cognition Platform. With 1,162 employees and 165 physicians/scientists serving 27,969 patients annually, the center combines care, research, and teaching missions as part of the Unicancer network.

Differentiator

Problem solved

Functional benefit

Brands

• Institut Normand du Sein: Breast cancer institute specializing in breast cancer treatment and care
• Centre de Protonthérapie de Normandie
• CEMAB
• Laboratoire de Biologie et de Génétique du Cancer

Products and services

• Protonthérapie (Proton Therapy) Advanced radiation therapy technique using proton beams to treat cancer with greater precision and reduced damage to surrounding healthy tissues. The center operates a Proteus One proton therapy system at the Cyclhad facility. Suitable for pediatric cancer patients and tumors requiring precise targeting with reduced toxicity.
• Radiothérapie (Radiotherapy)

Quantifiable outcome

• 27,969 patients treated in 2023
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

16 partnerships are on record, tiered core and minor.

• UnicancercoreStrategic or Co-development PartnerCentre François Baclesse is one of 18 cancer centers forming the Unicancer network in France. The network operates under shared values of Humanism, Innovation, Excellence, and Solidarity. This membership provides institutional recognition, research collaboration, and resource sharing across the French cancer center network.
• Inserm U1086 ANTICIPEcoreStrategic or Co-development PartnerResearch unit dedicated to cancer research integrated within the center's research activities.
• Inserm U1245 - Genetic predisposition to cancercoreStrategic or Co-development PartnerResearch unit focusing on genetic predispositions to cancer, integrated within the center's research activities.
• OECI (Organisation of European Cancer Institutes)coreStrategic or Co-development PartnerThe center holds OECI Comprehensive Cancer Center accreditation, joining the select group of European centers of excellence in cancer care. This partnership facilitates European collaboration and best practice sharing.
• CHU de CaenminorStrategic or Co-development PartnerParking facilities are owned by CHU de Caen. The center also collaborates with CHU on various research projects as evidenced by joint projects funded through La Rochambelle.
• IBA SAcoreTechnology or IntegrationEquipment provider for proton therapy system. The center uses Proteus One proton therapy machine supplied by IBA SA, installed in 2018.
• AccuraycoreTechnology or IntegrationEquipment provider for CyberKnife and Tomotherapy radiotherapy systems installed at the center.
• Varian Medical SystemscoreTechnology or IntegrationEquipment provider for Halcyon radiotherapy systems installed in 2022/2023.
• PhilipscoreTechnology or IntegrationEquipment provider for medical imaging including TEP-Scanner Vereos, Incisive CT scanner, and Aéra MRI system.
• Siemens HealthineerscoreTechnology or IntegrationEquipment provider for Confidence RT Pro scanner, INTEVO Bold gamma camera, and other medical imaging equipment.
• Golf Caen la MerminorGTM or Marketing PartnerAnnual Trophée Baclesse golf competition organized at Golf Caen la Mer to raise funds for supportive care services. Raised 2,665 euros in 2022.
• Lions Club de CoutancesminorGTM or Marketing PartnerTulipes contre le cancer operation raising funds for cancer research. Distributed nearly 600,000 euros since 1998 including 15,000 euros to Baclesse in 2022.
• Lions Club de FalaiseminorGTM or Marketing PartnerTulipes contre le cancer operation raising funds for cancer research. 34 years of support including 11,000 euros in 2022.
• La RochambelleminorGTM or Marketing PartnerSolidarity race/march raising funds for cancer projects. Raised 35,000 euros in 2022 shared between Baclesse (2 projects) and CHU de Caen.
• Rêves de VoyagesminorGTM or Marketing PartnerPatient support association raising nearly 200,000 euros over 20 years for patient comfort and well-being improvements at Baclesse.
• Les Sapins de l'EspoirminorGTM or Marketing PartnerCharitable association fully funding emergency analysis equipment (ABL90 FlexPlus blood gas analyzer) for the Cancer Biology and Genetics Laboratory.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Gustave Roussy: Largest comprehensive cancer center in France and fellow Unicancer CLCC. Comparable triple-mission (care/research/teaching) model, similar proton therapy and radiotherapy offerings, but with national/international brand reach far exceeding Baclesse's regional catchment.
• Institut Curie: Paris-based CLCC and one of France's three proton therapy sites (Orsay). Comparable care-research-teaching model, similar nuclear medicine and radiotherapy capabilities, and a comparable role as a regional referral hub.
• Centre Léon Bérard: Lyon-based CLCC in the Unicancer network with comprehensive oncology services including proton therapy. Directly comparable in mission, governance model, and equipment breadth, though operating in a different regional catchment.
• Centre Antoine Lacassagne: Nice-based CLCC and the third French proton therapy site. Operates the same Unicancer model with proton therapy, brachytherapy, and radiotherapy; directly comparable peer for technology portfolio and CLCC governance.
• Institut Bergonié: Bordeaux-based Unicancer CLCC with comprehensive oncology services, clinical research, and advanced radiotherapy. Comparable in size and regional positioning; directly comparable triple-mission operating model.
• Institut de Cancérologie de l'Ouest (ICO): Unicancer CLCC with sites in Angers and Nantes. Comparable comprehensive cancer center model with radiotherapy, surgery, and clinical research; regional player serving western France.
• European Institute of Oncology (IEO): Milan-based comprehensive cancer center with strong radiotherapy and clinical research focus. Comparable in mission mix (clinical care, research, teaching) and equipment intensity (advanced radiotherapy, nuclear medicine).
• Charité Comprehensive Cancer Center: Berlin-based OECI-accredited Comprehensive Cancer Center within Charité university hospital. Comparable triple-mission model, OECI accreditation status, and integrated research infrastructure (university hospital setting).

Broad incumbents

• The Royal Marsden NHS Foundation Trust: UK's largest comprehensive cancer center with international profile. Comparable in integrated care-research-teaching model and proton therapy capability, though operating under NHS commissioning rather than the French CLCC framework.
• The Christie NHS Foundation Trust: One of Europe's largest single-site cancer centers, operating the UK's first NHS high-energy proton therapy center. Comparable scale and equipment breadth (proton therapy, brachytherapy, advanced radiotherapy) to Baclesse's portfolio, though with significantly larger patient volumes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/BaclesseCaen

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centre François Baclesse